Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors
2017年7月7日 更新者:Peregrine Pharmaceuticals
Tumor Imaging of I-124 PGN65 in Solid Tumors
研究概览
详细说明
Up to 12 patients (6 men and 6 women) will be enrolled in this open-label, single-arm, tumor imaging and dosimetry study of I-124 PGN650 in solid tumors.
All eligible patients who give written, informed consent and meet all inclusion criteria and no exclusion criteria, and whose laboratory results are within specified limits at the screening visit, will be enrolled.
All study subjects will receive a single intravenous (IV) dose of I-124 PGN650.
Study subjects will have whole body PET/CT imaging at three different timepoints with all patients having PET/CT at 0 to 60 minutes after injection of I-124 PGN650.
Study subjects will then be assigned to either a 3 to 5-hour or 6 to 8-hour timepoint and either an 18 to 26 hour or 42 to 52 hour post-injection timepoint.
Tumor and whole body radioactivity distribution will be measured.
研究类型
介入性
注册 (实际的)
11
阶段
- 第一阶段早期
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Missouri
-
Saint Louis、Missouri、美国、63110
- Washington University School of Medicine, Siteman Cancer Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria
- Signed informed consent form.
- Male or female, ≥ 18 years of age.
- Histologically or cytologically confirmed solid tumors at any stage with at least one lesion (primary, metastatic, or recurrent) ≥ 1.5 cm in diameter documented by CT. If the lesion is located in a lymph node, the shortest diameter of the lymph node must be ≥ 1.5 cm as defined by RECIST 1.1. (Note: See Exclusion Criteria #1.)
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Adequate baseline hematological and organ function, assessed by laboratory values prior to study treatment as follows: absolute neutrophil count (ANC) > 1.0 x 109/L; hemoglobin > 7 g/dL; serum creatinine < 2 x institutional upper limit of normal (IULN); aspartate transaminase (AST) < 2.5 x IULN; alanine transaminase (ALT) < 2.5 x IULN; (if liver metastases are present, ALT and AST < 5 x IULN); total bilirubin < 1.5 x IULN.
- Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence), for the duration of study participation (i.e., from dosing day 1 until study day 8). Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Patient must be willing and able to undergo the imaging studies outlined in the protocol.
Exclusion Criteria
- Only measureable disease (primary or metastatic) is located in or near the thyroid gland, liver, kidney, or urinary bladder.
- Medical conditions such as ischemic heart or lung disease that may be considered an unacceptable risk.
- Females who are lactating or pregnant.
- Persistent acute toxicities from prior anti-cancer therapy.
- History of hypersensitivity to iodine.
- Known bladder outlet obstruction.
- Any condition that would in the Investigator's judgment prevents compliance with the requirements of the protocol.
- Patients with known history of an autoimmune disease- including but not limited to: celiac disease, Crohn's disease, dermatomyositis, Grave's disease, systemic lupus erythematosus, myasthenia gravis, psoriasis, and rheumatoid arthritis.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:I-124 PGN650 for PET/CT
|
I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
To estimate the intensity and distribution in critical and non-critical organs.
大体时间:Day 1
|
Day 1
|
|
To estimate the intensity and distribution in critical and non-critical organs.
大体时间:Day 2
|
Day 2
|
|
To estimate the intensity and distribution in critical and non-critical organs.
大体时间:Day 3
|
Day 3
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The presence of tumor imaging using I-124 PGN650 as a PS-targeting agent.
大体时间:Day 1, Day 2 and Day 3
|
Day 1, Day 2 and Day 3
|
|
Demonstrate the safety of tumor imaging in patients with solid cancers.
大体时间:Day 1, Day 2 and Day 3
|
Day 1, Day 2 and Day 3
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:Farrokh Dehsashti, M.D.、Washington University School of Medicine
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2012年6月1日
初级完成 (实际的)
2016年5月1日
研究完成 (实际的)
2016年5月1日
研究注册日期
首次提交
2012年6月12日
首先提交符合 QC 标准的
2012年6月28日
首次发布 (估计)
2012年7月3日
研究记录更新
最后更新发布 (实际的)
2017年7月11日
上次提交的符合 QC 标准的更新
2017年7月7日
最后验证
2017年7月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- PPHM 1201
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.